文献速递头颈与中枢神经肿瘤

真实世界环境中化疗联合西妥昔单抗一线治疗复发和/或转移性头颈癌患者的临床结局与预后因素

Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
PubMed 文献 · Eur J Cancer · 2019-05-10

这项在意大利6个肿瘤中心开展的真实世界回顾性观察纵向研究纳入2007年1月至2016年12月间接受铂类化疗联合西妥昔单抗一线治疗的297例复发/转移性头颈癌患者,中位总生存期为10.8个月(95%CI 9.3-12.2),中位无进展生存期为4.8个月(95%CI 4.3-5.5);多变量分析确定了总生存期、无进展生存期和客观缓解的不良预后因素。

要点

  • 297例复发/转移性头颈癌患者接受铂类联合西妥昔单抗一线治疗,中位总生存期10.8个月(95%CI 9.3-12.2)。
  • 中位无进展生存期为4.8个月(95%CI 4.3-5.5)。
  • ECOG体能状态>0、原发部位残留肿瘤、铂类耐药和缺乏客观缓解为总生存期独立不良预后因素。

核心结论

  • 新治疗手段的出现和流行病学变化使得定期重新评估预后因素对指导临床实践和设计未来随机临床试验具有重要意义。

研究设计与样本

  • 回顾性、观察性、纵向真实世界研究,纳入意大利6个肿瘤中心2007年1月至2016年12月间连续接受铂类化疗方案联合西妥昔单抗一线治疗的复发/转移性头颈癌患者,共297例。

主要发现

  • 中位总生存期为10.8个月(95%CI 9.3-12.2),中位无进展生存期为4.8个月(95%CI 4.3-5.5)。
  • 多变量分析中,总生存期的独立不良预后因素为ECOG体能状态>0、原发部位残留肿瘤、铂类耐药和缺乏客观缓解。
  • 无进展生存期的不良预测因素包括原发肿瘤部位(鼻旁窦、下咽)、ECOG体能状态>0、原发部位残留肿瘤、铂类耐药和缺乏客观缓解。
  • 客观缓解的独立不良预测因素为肿瘤部位(口腔、喉-下咽)、原发部位残留肿瘤和既往化疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aims of the study are to evaluate the clinical outcomes of first-line treatment with platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and neck cancer (RM HNC) and to identify predictors of treatment response. METHODS: This is a retrospective, observational, longitudinal, real-world study involving 6 oncology centres in Italy. All consecutive patients with RM HNC treated between January 2007 and December 2016 with a first-line therapy consisting of a platinum-based chemotherapy regimen plus cetuximab were included. The primary objective of the study was to assess overall survival (OS) and progression-free survival (PFS). Secondary objectives included the identification of predictors of treatment response. RESULTS: Overall, 297 patients were identified. Median OS was 10.8 months (95% confidence interval [CI] 9.3-12.2), whereas median PFS was 4.8 months (95% CI 4.3-5.5). On multivariable analysis, independent unfavourable prognostic factors for OS were performance status (PS) Eastern Cooperative Oncology Group (ECOG) >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Unfavourable predictors for PFS included cancer primary site (paranasal sinuses, hypopharynx), PS ECOG >0, presence of residual tumour at primary site, platinum resistance and lack of objective response. Independent unfavourable predictors of objective response were tumour site (oral cavity, larynx-hypopharynx), residual tumour at primary site and prior chemotherapy. CONCLUSIONS: The availability of new treatment modalities and epidemiological changes make the periodic reassessment of prognostic factors of great relevance to guide clinical practice and the design of future randomised clinical trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Depenni R, Cossu Rocca M, Ferrari D, et al. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. Eur J Cancer. 2019. PMID: 31082692. doi:10.1016/j.ejca.2019.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。